Become a Readings Member to make your shopping experience even easier. Sign in or sign up for free!

Become a Readings Member. Sign in or sign up for free!

Hello Readings Member! Go to the member centre to view your orders, change your details, or view your lists, or sign out.

Hello Readings Member! Go to the member centre or sign out.

Cart ⚙️
Home / HER2 and Cancer: Mechanism, Testing and Targeted Therapy
HER2 and Cancer: Mechanism, Testing and Targeted Therapy
Hardback

HER2 and Cancer: Mechanism, Testing and Targeted Therapy

$973.99
Add to wishlist
Sign in or become a Readings Member to add this title to your wishlist.

The HER2 receptor is a 185-kDa transmembrane glycoprotein with tyrosine kinase activity, and belongs in the human epidermal growth factor receptor (HER) family consisting of four members. Moreover, aberrant HER2 protein overexpression has been linked to various human gynecological adenocarcinomas, including breast, endometrium, ovary and cervix, and has been found to be a poor prognostic factor for survival. This new book presents topical research in the study of HER2, including targeting HER2 with photodynamic therapy; HER2 shedding as a biomarker in breast cancer; development of trastuzumab resistance and targeted nanomedicines conjugated with HER2 antibodies in cancer therapy.

Read More
In Shop
Out of stock
Shipping & Delivery

$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout

MORE INFO
Format
Hardback
Publisher
Nova Science Publishers Inc
Country
United States
Date
1 October 2011
Pages
245
ISBN
9781611226508

The HER2 receptor is a 185-kDa transmembrane glycoprotein with tyrosine kinase activity, and belongs in the human epidermal growth factor receptor (HER) family consisting of four members. Moreover, aberrant HER2 protein overexpression has been linked to various human gynecological adenocarcinomas, including breast, endometrium, ovary and cervix, and has been found to be a poor prognostic factor for survival. This new book presents topical research in the study of HER2, including targeting HER2 with photodynamic therapy; HER2 shedding as a biomarker in breast cancer; development of trastuzumab resistance and targeted nanomedicines conjugated with HER2 antibodies in cancer therapy.

Read More
Format
Hardback
Publisher
Nova Science Publishers Inc
Country
United States
Date
1 October 2011
Pages
245
ISBN
9781611226508

Looking for something in particular?

Search our extensive online catalogue.